New hope for hard-to-treat cancers? early trial of XNW28012 begins
NCT ID NCT06799637
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This study tests a new drug, XNW28012, in people with advanced solid tumors (like pancreatic, ovarian, or cervical cancer) who have not responded to or cannot tolerate standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 350 participants will take part in two phases: first finding the right dose, then testing how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, China
-
Affiliated Hospital of Binzhou Medical College
RECRUITINGBinzhou, Shandong, China
-
Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, China
-
Affiliated Hospital of Hebei University
RECRUITINGBaoding, Hebei, China
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, China
-
First Affiliated Hospital of Gannan Medical College
RECRUITINGGanzhou, Jiangxi, China
-
First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, Henan, China
-
First Affiliated Hospital of Kunming Medical University
RECRUITINGYunnan, Kunming, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
-
Fujian Provincial Cancer Hospital
RECRUITINGFuzhou, Fujian, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, China
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, China
-
Linyi Cancer Hospital
RECRUITINGLinyi, Shandong, China
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, China
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of University of Science and Technology of China
RECRUITINGHefei, Anhui, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
-
The Second Xiangya Hospital Of Central South University
RECRUITINGChangsha, Hunan, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Yunnan Cancer Hospital
RECRUITINGKunming, Yunnan, China
Conditions
Explore the condition pages connected to this study.